Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Trying to decide which is better: cash back or points credit cards? Analyze your spending habits to make the best choice for maximizing rewards.
27,088 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
As Micron Technology rides AI-driven memory demand, investors debate a bold forecast. Market models suggest a potenti...
A 73-year-old worker with an $800,000 401(K) cannot roll it into a new IRA after leaving a former employer, revealing...
NovaCore Technologies enters the second half of 2026 with a multi-year backlog, AI revenue momentum, and cloud growth...
Bitcoin miners start funding AI pivots by borrowing and selling BTC to stay liquid as margins tighten, hash prices fa...
Prices stay higher than a few years ago, eroding cash savings. A trio of ETFs—GLD, VTIP, and DBC—are positioned to he...
Oil edges toward a $100 threshold as geopolitical tensions intensify. Four key energy names—Exxon, Chevron, ConocoPhi...
A growth stock has fallen sharply, trading hands at levels that look oversold. This article breaks down whether the d...
Synopsys, a leader in chip design software, trades below its 52-week high even as revenue grows, highlighting investo...
With Johnson & Johnson stock hovering near mid-230s, investors are weighing if a $300 target is in reach this year as...
Carnival sailed to another quarter of record yields, yet its shares lag Royal Caribbean as debt, pricing power, and c...
Nike delivered a quarterly beat that sent its shares higher, but investors kept a close eye on tariffs and future gui...